Ambry Genetics and collaborator Akcea Therapeutics have launched hATTR Compass, a novel genetic testing program that will help people with suspected hereditary transthyretin amyloidosis through free, confidential analyses and genetic counseling. Ambry will provide testing services for people age 18 and older living in the US or Canada; the mobile app Backpack Health will allow for symptom tracking; and confidential genetic counseling will be provided through program partner PWNHealth, a virtual care company.
Novel hereditary ATTR amyloidosis genetic testing program launched
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.